Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $421.7 million.

  • Corcept Therapeutics' Cash & Current Investments rose 1087.12% to $421.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $421.7 million, marking a year-over-year increase of 1087.12%. This contributed to the annual value of $383.3 million for FY2024, which is 410.43% up from last year.
  • Corcept Therapeutics' Cash & Current Investments amounted to $421.7 million in Q3 2025, which was up 1087.12% from $342.2 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Cash & Current Investments peaked at $473.2 million during Q2 2024, and registered a low of $223.5 million during Q4 2021.
  • For the 5-year period, Corcept Therapeutics' Cash & Current Investments averaged around $376.7 million, with its median value being $370.1 million (2022).
  • In the last 5 years, Corcept Therapeutics' Cash & Current Investments tumbled by 4927.68% in 2021 and then skyrocketed by 9311.16% in 2022.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Cash & Current Investments stood at $223.5 million in 2021, then surged by 93.11% to $431.7 million in 2022, then decreased by 14.7% to $368.2 million in 2023, then grew by 4.1% to $383.3 million in 2024, then rose by 10.0% to $421.7 million in 2025.
  • Its last three reported values are $421.7 million in Q3 2025, $342.2 million for Q2 2025, and $322.8 million during Q1 2025.